HER2 alteration is a rare but widely acknowledged oncogenic driver of non‐small cell lung cancer (NSCLC), which includes HER2 overexpression, amplification, and gene mutation with incidence rates of 7.7%–23%, 2%–22%, and 1%–6.7%, respectively [1]. This evidence concerns the gene ERBB2 and lung cancer.